NCT07058077View on ClinicalTrials.gov

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

153

Participants

Timeline

Start Date

August 21, 2025

Primary Completion Date

December 4, 2033

Study Completion Date

January 24, 2037

Conditions

Heterozygous Familial Hypercholesterolemia (HeFH)

Interventions

DRUG

Enlicitide Decanoate

Enlicitide decanoate taken by mouth

DRUG

Placebo

Placebo tablet matched to enlicitide decanoate taken by mouth

Trial Locations (2)

19803

RECRUITING

Nemours/Alfred I. duPont Hospital for Children (0001), Wilmington

33434

RECRUITING

Excel Medical Clinical Trials (0008), Boca Raton

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT07058077 - A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) | Biotech Hunter | Biotech Hunter